Calcineurin Inhibitor Immunosuppressant — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the calcineurin inhibitor immunosuppressant class. 47 active patents protecting 2 drugs. First major cliff: 2028. Daily refresh.

2
Drugs in class
47
Active US patents
63/100
Avg vulnerability
$3.5B
Annual revenue covered

Originators

Astellas Pharma 30 patents Novartis AG (originally Sandoz) 17 patents

Cliff calendar — next 15 years

1
27
30
28
1
29
1
30
1
31
1
32
3
33
2
34
1
36
3
37
1
38
1
39

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prograf
TACROLIMUS
 Astellas Pharma 30 70 $1.6B 2028-05-30
Sandimmune
cyclosporine
 Novartis AG (originally Sandoz) 17 55 $1.9B 2027-11-03

Most attackable patents

Patent Drug Type Vuln Expiry
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
11110081 Prograf method of use 75 2028-05-30
11110081 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30

Strongest defences

Patent Drug Type Vuln Expiry
10918694 Sandimmune formulation 42 2037-02-28
9669974 Sandimmune formulation 42 2034-05-11
9676525 Sandimmune formulation 42 2034-02-07
10441630 Sandimmune formulation 42 2033-08-23
8561859 Sandimmune formulation 48 2032-04-16
8292129 Sandimmune formulation 48 2031-02-25
9132071 Sandimmune formulation 48 2029-06-02
10813976 Sandimmune formulation 50 2037-09-22
10166190 Prograf formulation 55 2028-05-30
10166190 Prograf formulation 55 2028-05-30

Related